Many adults in the United States view the use of weight loss medications, such as Ozempic and Wegovy, as a positive option for those struggling with obesity or related health conditions. However, attitudes differ significantly when it comes to adolescents facing obesity. A recent survey by The Associated Press and NORC Center for Public Affairs Research reveals that while around one-third of Americans find it acceptable for teens aged 12 to 18 to use these medications, an equal number disapprove, and around 30% remain neutral.
When focusing solely on adults, about half see these medications as beneficial, while two out of ten believe they are detrimental.
The weight loss medications in question function as GLP-1 receptor agonists, initially intended for diabetes management. Their popularity surged in 2021 after the FDA approved them for weight loss. Today, they are frequently discussed in popular media, from celebrity endorsements to social media chatter.
Medical professionals argue that these injectable medications are effective tools in combating obesity. The American Medical Association encourages health insurance companies to cover them, and the American Academy of Pediatrics suggests doctors consider prescribing these medications to adolescents dealing with obesity. Yet, public opinion indicates that despite some professional endorsements, many Americans harbor concerns, particularly relating to their use among teenagers and those who aren’t classified as obese.
According to the Centers for Disease Control and Prevention (CDC), over 100 million adults in the U.S. are classified as obese, defined as having a body mass index (BMI) of 30 or higher. Out of these, more than 22 million struggle with severe obesity, a BMI of 40 or greater. Obesity is recognized as a chronic health issue needing medical attention, influenced by factors like genetics, environment, and socioeconomic status. However, those who use medications to manage their weight might face stigma, as some perceive it as an unfair advantage in the weight loss journey.
Anjanette Ewen is one individual who successfully lost over 30 kilos with the help of Mounjaro. She shared that her weight loss journey, compounded by complications from polycystic ovary syndrome, made it challenging to manage her weight. Ewen emphasized how this loss ultimately allowed her to identify a concerning health issue, underscoring the potential benefits these medications can provide.
Currently, about 20% of children in the U.S. are affected by obesity, according to CDC data. Dr. Gitanjali Srivastava from Vanderbilt University emphasizes that obesity treatments are often more effective in children than in adults, warning that early onset obesity can lead to severe issues later in life.
Insurance coverage for these weight-loss medications remains a contentious topic. Without insurance, the out-of-pocket costs can reach hundreds of dollars for each prescription. The survey indicates that around half of Americans support federal programs like Medicare and Medicaid covering weight loss medications for individuals with obesity, while two out of ten oppose this idea.
At present, Medicare does not cover obesity medications, though Medicaid’s coverage can vary. Some larger employers are beginning to include this coverage in their benefits, but many others are cutting it due to treatment costs.
There’s also concern regarding the use of GLP-1 medications among those who are not obese. About 60% of Americans believe it is wrong for adults to take these medications without a diagnosis of obesity, and this sentiment increases to 70% when discussing teenagers. Interestingly, younger adults are slightly more open to the idea of teens using these medications, but a significant majority of older adults strongly disagree.
In conclusion, while the conversation around the use of weight loss medications continues, particularly regarding their use in adolescents, there is a clear divide in public opinion. As the issue evolves, it raises important questions about health, responsibility, and the comprehensive treatment of obesity in American society.
